Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume

BACKGROUND: Anti-PD-(L)1 treatment is indicated for patients with mismatch repair-deficient (MMRD) tumors, regardless of tumor origin. However, the response rate is highly heterogeneous across MMRD tumors. The objective of the study is to find a score that predicts anti-PD-(L)1 response in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Belkouchi, Younes, Nebot-Bral, Laetitia, Lawrance, Littisha, Kind, Michele, David, Clémence, Ammari, Samy, Cournède, Paul-Henry, Talbot, Hugues, Vuagnat, Perrine, Smolenschi, Cristina, Kannouche, Patricia L., Chaput, Nathalie, Lassau, Nathalie, Hollebecque, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641225/
https://www.ncbi.nlm.nih.gov/pubmed/36387101
http://dx.doi.org/10.3389/fonc.2022.982790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641225/
https://www.ncbi.nlm.nih.gov/pubmed/36387101
http://dx.doi.org/10.3389/fonc.2022.982790

Ejemplares similares